ARL8B Activators
ARL8B activators represent a distinct chemical class known for their ability to modulate the activity of the ARL8B protein, a member of the ADP-ribosylation factor (ARF) family. ARL8B, short for ADP-ribosylation factor-like 8B, is a small GTPase that plays a crucial role in cellular processes such as vesicular trafficking, lysosomal positioning, and autophagy. The chemical entities classified as ARL8B activators exert their influence by promoting the activation of ARL8B, thereby influencing downstream cellular pathways. These compounds typically interact with specific molecular targets or cellular components involved in the regulation of ARL8B, facilitating its activation and subsequent participation in intracellular transport and organelle positioning.
The structural characteristics of ARL8B activators vary, reflecting the diversity within this chemical class. Researchers have identified compounds that possess the ability to bind to ARL8B directly or interact with proteins associated with its activation pathway. Through these interactions, ARL8B activators fine-tune the cellular machinery involved in membrane trafficking and lysosomal dynamics. The modulation of ARL8B activity by these compounds presents opportunities for investigating the underlying mechanisms of intracellular transport processes and may contribute to a deeper understanding of cellular homeostasis. As scientists continue to explore the intricate details of ARL8B activation and its consequences, ARL8B activators remain valuable tools in unraveling the complexities of cellular physiology and molecular pathways governing vesicular trafficking.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin directly stimulates adenylate cyclase, leading to increased production of cyclic AMP (cAMP), a secondary messenger that enhances the activity of ARL8B by promoting the cAMP-dependent pathway, which is known to be involved in vesicle trafficking, a process ARL8B regulates. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates protein kinase C (PKC), which in turn can phosphorylate proteins involved in vesicular transport. ARL8B, being a small GTPase involved in vesicular trafficking, would have its functional activity enhanced as the phosphorylation status of proteins within its pathway alters vesicle dynamics. | ||||||
Ionomycin, free acid | 56092-81-0 | sc-263405 sc-263405A | 1 mg 5 mg | $94.00 $259.00 | 2 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels, activating calcium-dependent signaling pathways. Elevated calcium may enhance ARL8B function by modulating the activity of calcium-dependent proteins that interact with ARL8B, affecting vesicle formation and mobility. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a kinase that negatively regulates autophagy. Inhibition of mTOR can enhance autophagy, a process in which ARL8B is implicated. Enhanced autophagy would thus indirectly increase the functional demand and activity of ARL8B. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $148.00 $597.00 | 75 | |
NSC23766 inhibits Rac1, another small GTPase. The inhibition of Rac1 can result in reorganization of the actin cytoskeleton, which may promote the functions of ARL8B in vesicular trafficking through altered cytoskeletal dynamics. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $260.00 $799.00 | 36 | |
Latrunculin A binds to actin monomers and prevents polymerization, disrupting cytoskeletal dynamics. This disruption can lead to enhanced vesicle trafficking processes, potentially elevating the functional activity of ARL8B. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $58.00 $83.00 $140.00 $242.00 | 38 | |
Nocodazole disrupts microtubule polymerization, affecting microtubule dynamics. As ARL8B is involved in microtubule-dependent vesicle transport, nocodazole-induced microtubule disruption can increase the requirement for ARL8B function. | ||||||
Jasplakinolide | 102396-24-7 | sc-202191 sc-202191A | 50 µg 100 µg | $180.00 $299.00 | 59 | |
Jasplakinolide stabilizes actin filaments and thus can alter actin dynamics. By stabilizing actin filaments, it could enhance the functional activity of ARL8B by affecting the interaction of vesicles with the actin cytoskeleton. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 is a p38 MAPK inhibitor. By inhibiting p38 MAPK, it can affect downstream signaling that interfaces with the cytoskeleton and vesicle trafficking, potentially enhancing ARL8B activity related to these processes. | ||||||